Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies - Takeaways - MDSpire

Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies

  • By

  • Athanasios Tsianakas

  • Nina Magnolo

  • Afra Kempf

  • Frank Andersohn

  • Astrid Kirsch

  • Georgios Kokolakis

  • Dennis Niebel

  • March 28, 2026

  • 0 min

Share

  • 1

    Tildrakizumab is approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

  • 2

    The meta-analysis synthesized data from four observational studies focusing on diverse psoriasis populations in Germany.

  • 3

    Tildrakizumab showed positive outcomes across studies for Psoriasis Area Severity Index and quality of life at week 28.

  • 4

    The results support tildrakizumab's reliability in treating heterogeneous patient profiles with plaque psoriasis.

  • 5

    Real-world data confirm the effectiveness and safety of tildrakizumab, addressing gaps in randomized clinical trials.

Original Source(s)

Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies

  • by Athanasios Tsianakas, Nina Magnolo, Afra Kempf, Frank Andersohn, Astrid Kirsch, Georgios Kokolakis, Dennis Niebel

  • March 28, 2026

Related Content

Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation